Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. - Wikidata - wikimedia - TriplyDB

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

http://www.wikidata.org/entity/Q35226511

about

Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses Oncolytic virotherapy for human malignant mesothelioma: recent advances Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.Measles to the Rescue: A Review of Oncolytic Measles Virus The use of the NIS reporter gene for optimizing oncolytic virotherapy Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma Positive radionuclide imaging of miRNA expression using RILES and the human sodium iodide symporter as reporter gene is feasible and supports a protective role of miRNA-23a in response to muscular atrophy Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer Oncolysis by paramyxoviruses: preclinical and clinical studies.Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.How to develop viruses into anticancer weapons.Development of new therapy for canine mammary cancer with recombinant measles virus.Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors Cell-to-Cell Contact and Nectin-4 Govern Spread of Measles Virus from Primary Human Myeloid Cells to Primary Human Airway Epithelial Cells Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers.Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.Oncolytic immunotherapy: The new clinical outbreak.Fighting Cancer with Mathematics and Viruses.Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Potential and clinical translation of oncolytic measles viruses.Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.Advances in the design and development of oncolytic measles viruses.The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells.Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.Hematopoietic cancer cell lines can support replication of Sabin poliovirus type 1.Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma.Oncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics.Measles Vaccine.Review: Oncolytic virotherapy, updates and future directions.

P2860

Q26700080-F976C4D2-16D1-42A0-8E57-8E41AFFC6954 Q26752807-9D813C24-78B8-42C8-A777-53A4F64B2209 Q26826590-1CB8A9AA-6417-47FB-81D0-47363A23A210 Q27340224-E8722A4F-2E79-459C-9042-E9B0B2B4A129 Q28072097-D2027AEF-EDCE-46B4-9E8E-2322BBA99679 Q28083534-8185B65B-0CE4-4655-9C78-F1FE8722D050 Q30369123-B21D23A7-379E-41C0-BE62-B1F74FFBA166 Q33441321-67425582-9FE9-42F6-B610-C4CD9F4A3C7C Q33664375-61E6FCD2-FBCB-47FF-9F5A-447A8081C19B Q33899522-633D1537-2277-416C-ABD6-0990D460A817 Q33904378-77D64968-E0E2-454D-9F65-B7557164E120 Q34997475-DB849E3A-9119-47F5-89D2-E80D4737F589 Q35861933-836B82D1-4CA8-4970-A845-FDB3ADE375F2 Q36108892-34CDF4E7-3D4A-4FCD-84A5-8BE06E7FE6CE Q36310887-21D99E32-7ED5-47CD-AB99-FAE65A730D83 Q36664263-3A53B17F-460E-4C44-8692-F3B63ED09140 Q36664268-EBC25D84-EEB2-40B0-91E5-2317E43B5255 Q36777139-95C7D36A-C302-4C96-BC3D-0431390E62D6 Q37093457-5CF226E2-2069-47D2-B122-90CDE9F271CB Q37437450-4C563ED7-AB86-4893-A951-DF8C690C6D8F Q37452241-2E8E31F2-05C8-49F7-8921-8DC78234B907 Q37687542-223078BA-015F-4A61-BCCB-7036BF5FEF12 Q38564425-EC972B50-4A83-4CDF-83B2-8B03E9EBD6DB Q38612646-E5716DF7-66A6-4BD1-86E9-578E7DA0DE18 Q38754467-B512619F-BEF2-40BC-9D5E-7B1ACF32A484 Q38764947-D81A200D-2442-4389-873C-8D7B4ED9EC46 Q38772380-1F477F80-AD94-4844-A925-34F9E210A159 Q38799217-57EB0063-6AF9-472E-8A32-D57B11BFD919 Q38845173-1F8F2C4B-AF54-4DBC-AEFC-A32145A86F58 Q38924566-72BEBC2F-D84F-4105-A0DC-AC85FE543341 Q39133291-B6099ADE-E4BE-4415-BFF2-C1FDE8C96985 Q40066397-FBEE6822-9712-456F-9766-4BEFC60E2195 Q40336053-86C2A8AC-A45F-463E-9EFA-757131DCE408 Q40529135-E5DAC8EE-ECD5-4D7B-913E-960870B4811E Q41150238-C2E8FD5C-AFBF-43AD-A7D1-ABAF02B8B72D Q41699675-DB3867A4-143E-41B8-8814-1C475A101BA0 Q41926374-9899633F-0E17-45C8-B3D1-CCE9DA3C32A4 Q46265659-993908C0-6A27-4D88-85C8-22A0FC985BDE Q46300761-76003121-A6E9-4480-B1F6-A2E5A32DFB3A Q47160989-0D7B8986-8D08-4F25-ADAC-EE888856F1BE

P2860

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

http://www.wikidata.org/entity/Q35226511

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@ast

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@en

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@en-gb

type

label

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@ast

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@en

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@en-gb

prefLabel

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@ast

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@en

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@en-gb

P1433

Q35226511-182CE80A-64A4-4DE8-9294-2B9D7B7D318D

P1476

Q35226511-410BA709-19D8-4720-9697-4B22E3640ABB

P2093

Q35226511-02602E13-D763-4968-91FD-34C79FD26A23

Q35226511-12F66E8E-DDD7-4220-922E-915355092AB8

Q35226511-1DE9E416-35D0-4BF4-8C52-1ABEDFF829E9

Q35226511-287DE5C5-2DD8-48B7-AB04-0FA9283AC425

Q35226511-475ED703-03F5-48A5-885A-14CB8CED3DF9

Q35226511-5332D3B1-04D4-4554-9B82-774443830B89

Q35226511-5C517EBE-20D6-4B27-B1D9-644D563A67C4

Q35226511-5FE82DBD-E0CA-4AE4-8973-3B097457383A

Q35226511-6584BDEE-833D-4B62-AC59-985F8D489EAD

Q35226511-72569E34-DD29-46BB-975D-D9FDAC0A5133

P2860

Q35226511-02D3D6A2-7262-4AB4-BB50-253D305F3AD7

Q35226511-24BF7ACF-91D5-456C-9868-E7782398097E

Q35226511-290E43C0-927B-4D36-BCF9-53D90A627AC2

Q35226511-315606E2-C46C-4EE6-A5FD-9764B2E46C82

Q35226511-353C1DC2-E241-4BBA-863B-50726F7C0B0F

Q35226511-363D7F3A-C8ED-46EC-9A6C-D4A31201D25F

Q35226511-3AE88368-9E2F-42F2-A4FC-C626558F9735

Q35226511-47F9226C-1DC4-420C-B95E-331D30771DDE

Q35226511-4EE85598-473F-4877-8445-AFF9E8E4326E

Q35226511-4FF481A2-FF54-4C9E-A7AA-EC234102426C

P304

Q35226511-ACDFDC37-3830-4F61-B1CB-D343B6EEA7CB

P31

Q35226511-6234BB96-CAB2-4D44-9459-95AE97C37F85

P356

Q35226511-DEB2D7BF-67A7-428B-88ED-3E6FAB41F1BE

P407

Q35226511-3F373FB1-45C3-4814-9EC7-7CE0FD773B9D

P433

Q35226511-71580A96-2DE4-4613-A90A-0B13EF4C35F5

P478

Q35226511-1026E8CD-A247-47FC-B0CC-7EE6BB18ECB6

P50

Q35226511-59B8E68A-D54C-4078-81E7-901AAC7EB389

Q35226511-BBC1D0F0-34FE-4AAC-B095-BFC5DD05DC06

Q35226511-C0091461-D307-4AB4-A262-58D4F6F506BE

P577

Q35226511-48216126-0720-4E1A-A2E8-438C92A2D044

P698

Q35226511-AC8ABC58-718D-4F6A-9F62-B5D24B03EAAA

P921

Q35226511-0C870BF4-780F-49DE-879D-8E69AE544CB1

Q35226511-800A08B1-6F2E-4A96-979C-DBFCA8E41E3E

Q35226511-F6EB81B8-AE92-4478-976F-64F333B988C4

P932

Q35226511-4E46C1E3-EFA7-4384-B1B2-C8A8FBC3394B

P356

0008-5472.CAN-14-2533

P1433

Cancer Research

P1476

Oncolytic measles virus expres ...... drug-resistant ovarian cancer.

@en

P2093

Ann Oberg

http://www.w3.org/2001/XMLSchema#string

Gary Keeney

http://www.w3.org/2001/XMLSchema#string

Harry J Long

http://www.w3.org/2001/XMLSchema#string

Ileana Aderca

http://www.w3.org/2001/XMLSchema#string

Jamie Bakkum-Gamez

http://www.w3.org/2001/XMLSchema#string

Keith L Knutson

http://www.w3.org/2001/XMLSchema#string

Kimberly R Kalli

http://www.w3.org/2001/XMLSchema#string

Lynn C Hartmann

http://www.w3.org/2001/XMLSchema#string

Mark J Federspiel

http://www.w3.org/2001/XMLSchema#string

Matthew J Maurer

http://www.w3.org/2001/XMLSchema#string

P2860

Adherens junction protein nectin-4 is the epithelial receptor for measles virus

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer statistics, 2014

SLAM (CDw150) is a cellular receptor for measles virus

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.

A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

P304

22-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-14-2533

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Stephen J Russell

Evanthia Galanis

P577

2014-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25398436

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

4377302

http://www.w3.org/2001/XMLSchema#string